Inclusivity of patients in early phase breast cancer clinical trials☆

被引:0
|
作者
Sinha, A. [1 ]
Barwell, L. [1 ]
Jeffery, H. [1 ,2 ]
Peterson, Z. [1 ,2 ]
Shifa, B. [1 ,2 ]
Attia, M. [2 ,3 ]
Badawy, K. [1 ]
Purushotham, A. [1 ,2 ]
机构
[1] Kings Coll London, London, England
[2] Guys & St Thomas NHS Fdn Trust, London, England
[3] Cairo Univ, Fac Med, Dept Gen Surg, Cairo, Egypt
来源
JOURNAL OF CANCER POLICY | 2024年 / 41卷
关键词
Diversity; Clinical Trials; Recruitment; Ethnicity; UNDER-REPRESENTATION; STREPTOMYCIN;
D O I
10.1016/j.jcpo.2024.100494
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Studies have shown that certain groups of patients are underrepresented in clinical trials including non-Caucasian ethnicity, poor fluency in English, low socioeconomic status, older age, neurodivergence, and large Body Mass Index (BMI). There is a need to ensure adequate representation of these groups so that the results of any trial accurately reflect the population. The aim of this study was to review the pathway of patients recruited into two early phase breast cancer clinical and determine the inclusivity of patients from the aforementioned sub-groups. Methods: The Breast Cancer Research Database was reviewed, and the characteristics of all patients who were screened for eligibility in two early phase clinical trials was examined. The English Indices of Deprivation was used to populate the Index of Multiple Deprivation (IMD) for each patient using their postcode. Results: In total, 392 patients were eligible to participate, between September 2020 to May 2023. Of these, 144 (36.7 %) were recruited to these two trials. In all, 100 % of patients eligible for these trials were approached and screened for participation. Eligible patients had a mean age of 53.5 years. Recruited patients were younger on average than those not recruited (49.1 years vs 56.0 years, p<0.0001). Only one recruited patient required an interpreter, compared with 24 (9.7 %%) of those who were not recruited (p<0.001). There was no difference in the IMD (p=0.38), BMI (p=0.34) and neurodiversity (p=0.10) between patients recruited into clinical trials and those who were not. Conclusion: Older age and poor fluency in the English language remain barriers to participation in early-phase clinical trials despite implementing a clear pathway to trial recruitment. There is a pressing need to address these barriers by raising awareness, improve appropriate training and providing comprehensive trial information to patients in the language of their choice.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Participation of Hypertension Patients in Early-Phase Clinical Trials
    Borron, Paul
    Cohen, Oren
    Hoofwijk, Theo J.
    Turner, J. Rick
    JOURNAL OF CLINICAL HYPERTENSION, 2014, 16 (06): : 389 - 392
  • [32] CLINICAL-TRIALS AND LOCAL TREATMENT OF EARLY BREAST-CANCER
    FORBES, JF
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (06): : 419 - 421
  • [33] ATP chemosensitivity testing in ovarian and breast cancer:: Early clinical trials
    Kurbacher, CM
    Grecu, OM
    Stier, U
    Gilster, TJ
    Janát, MM
    Untch, M
    Konecny, G
    Bruckner, HW
    Cree, IA
    CHEMOSENSITIVITY TESTING IN ONCOLOGY, 2003, 161 : 221 - 230
  • [34] Choosing relevant endpoints for older breast cancer patients in clinical trials: an overview of all current clinical trials on breast cancer treatment
    N. A. de Glas
    M. E. Hamaker
    M. Kiderlen
    A. J. M. de Craen
    S. P. Mooijaart
    C. J. H. van de Velde
    B. C. van Munster
    J. E. A. Portielje
    G. J. Liefers
    E. Bastiaannet
    Breast Cancer Research and Treatment, 2014, 146 : 591 - 597
  • [35] Choosing relevant endpoints for older breast cancer patients in clinical trials: an overview of all current clinical trials on breast cancer treatment
    de Glas, N. A.
    Hamaker, M. E.
    Kiderlen, M.
    de Craen, A. J. M.
    Mooijaart, S. P.
    van de Velde, C. J. H.
    van Munster, B. C.
    Portielje, J. E. A.
    Liefers, G. J.
    Bastiaannet, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (03) : 591 - 597
  • [36] Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
    Poon, J.
    Aktas, B. Y.
    Kristeleit, R.
    Josephs, D.
    Spicer, J.
    Sarker, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S947 - S947
  • [37] Evolution and landscape of clinical trials for breast cancer patients.
    Dogan, Semih
    Goubar, Aicha
    Arnedos, Monica
    Delaloge, Suzette
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Increasing accrual of minority patients in breast cancer clinical trials
    Amelia A. Trant
    Lucas Walz
    Whitney Allen
    Jose DeJesus
    Christos Hatzis
    Andrea Silber
    Breast Cancer Research and Treatment, 2020, 184 : 499 - 505
  • [39] Outcome of Breast Cancer Patients Treated outside of Clinical Trials
    El Saghir, Nagi S.
    Assi, Hussein A.
    Jaber, Sara M.
    Khoury, Katia E.
    Nachef, Zahi
    Mikdashi, Hana F.
    El-Asmar, Nadine S.
    Eid, Toufic A.
    JOURNAL OF CANCER, 2014, 5 (06): : 491 - 498
  • [40] Informed consent for clinical trials in older patients with breast cancer
    Bowmer, C.
    Ring, A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 72 : S32 - S32